LiangYiHui Secures Tens of Millions in Series B Funding to Advance Integrated Oncology Care Platform for Doctors, Patients, and Enterprises

Innovation, investment, and reform in the field of oncology are focal points of global attention. As cancer diagnosis and treatment enter the era of precision medicine, concepts in oncological careInnovationTechnology andInnovationPharmaceuticals are advancing at a rapid pace. In this process, it has become particularly crucial for oncologists and patients to update their knowledge and concepts in a timely manner. New technologies such as the Internet, big data, and artificial intelligence will play an important role in this transformation. Liangyi Hui, asChina's Most Professionalan oncology patient-physician service platform that connects knowledge, doctors, patients, and enterprises, providing a one-stop online and offline professional oncology service platform, which will also become an indispensable part of the oncology diagnosis and treatment systemMinorpart of.

On November 18, 2018, VCBeat learned exclusively that Liangyihui, a leading domestic professional academic platform for oncology, had completed its Series B financing round. The round amounted to tens of millions of RMB and was solely invested by Danlu Capital.

Danlu Capital is a venture capital firm focused on the healthcare and medical industry, co-founded in early 2018 by Lu Qinchao, former partner at Sequoia Capital China, and Su Zhenbo, former managing partner of Fenxiang Investment Management. Headquartered in the CTF Finance Center in Zhujiang New Town, Guangzhou, its core team members all come from well-known domestic venture capital funds, possessing deep insights into investment and industry dynamics, along with a strong track record of historical investment performance. This financing round for Liangyi Hui marks another endorsement by professional institutional investors, following its earlier investment by Legend Capital, a renowned healthcare-focused investment firm.

It is reported that following this round of financing, Liangyi Hui will further deepen and refine its professional content and online-offline service systems tailored for oncologists, patients, and enterprises.

LiangYiHui was founded in 2014. Starting with content creation, the company is committed to addressing information asymmetry in oncology diagnosis and treatment, providing efficient tools for oncologists, and conducting science popularization and clinical services for cancer patients and the general public. LiangYiHui maintains close collaborations with professional associations and cancer hospitals both domestically and internationally. Its subsidiary platform, Oncology News, is the official cooperative platform of the Chinese Society of Clinical Oncology (CSCO).

The founding team of Liangyihui comes from leading pharmaceutical companies and consulting firms in the industry. Core members all have more than 10 years of experience in the oncology sector, as well as extensive experience in the internet field. Co-founder Wang Jue holds a Master’s degree in Clinical Medicine.Over 10 Years of Experience in the Medical FieldWith 13 years of experience in oncology at multinational pharmaceutical companies; Co-founder Wang Junqing graduated from the Massachusetts Institute of Technology and holds an MBA from the University of Michigan’s Ross School of Business. He has work experience in both the internet and pharmaceutical industries, with many years at Oracle, Deloitte, and Eli Lilly and Company. Co-founder Ms. He Hongjuan has worked in multinational pharmaceutical companies for over 20 years. Before joining Liangyihui, she was the National Sales Head of the Oncology Division at Eli Lilly and Company.

In addition to extensive industry experience in oncology and professional resources both domestically and internationally, the team also comprises talent with cross-industry work experience, possessing expertise in internet technologies, big data, and deep learning algorithms.

The 5-year survival rate for cancer patients in China differs by more than 30% from that in foreign countries, a disparity driven by multiple factors. First, early diagnosis and treatment are inadequate, with many patients diagnosed only at advanced stages (Stage III or IV). Second, treatment practices lack standardization; although oncology has advanced rapidly in recent years, the competence of physicians in China varies significantly, and the standard multidisciplinary team (MDT) approach to cancer care is only just beginning to gain traction domestically. Third, access to innovative drugs is limited. Fourth, the high cost of anticancer medications remains a significant barrier.

Late diagnosis, poor treatment efficacy, scarcity of new drugs, high drug prices, and limited patient financial protection... Throughout this process, neither physicians nor patients are satisfied with the outcomes of diagnosis and treatment. How can we achieve satisfaction with all treatments? A crucial step is to improve the cost-effectiveness ratio.

Improving therapeutic efficacy and reducing costs constitute the most fundamental solution. Within the oncology diagnosis and treatment system, oncologists occupy a pivotal core position, as their clinical proficiency directly determines treatment outcomes. However, China faces a significant shortage of high-quality oncology specialists. Furthermore, since physicians from numerous clinical departments in China are involved in cancer care, there is an urgent need to enhance their knowledge of new developments, adopt updated concepts, and standardize diagnostic and therapeutic practices. It is imperative to address this issue by leveraging professional information channels and internet-based platforms to improve physicians’ treatment standards and conceptual frameworks, facilitate the decentralization of high-quality diagnostic and therapeutic resources, and expand the service reach and capacity of skilled physicians.

Since its inception, the company has been committed to building a platform dedicated to serving all stakeholders in the oncology ecosystem. Providing professional information and addressing information asymmetry constitute the most critical and fundamental entry point.

Since 2010, when the company launched its information platform “Oncology News,” it has been providing high-quality original academic content services to oncologists and patients in China. Wang Jue believes that accurate academic information is key to improving physicians’ diagnostic and treatment capabilities.

Based onGuided by this philosophy, LiangYiHui has collaborated with professional societies, hospitals, and experts both in China and abroad. It has accumulated over 50,000 pieces of original academic content and hosted more than 1,000 open academic lectures, while also launching an academic Q&A community specialized in oncology. Reportedly, LiangYiHui’s suite of products now reaches over 60% of oncologists in China, with more than 60% of these users affiliated with Grade III Class A hospitals or specialized hospitals, and over 60% being senior physicians (including chief physicians, associate chief physicians, and attending physicians with more than three years of experience). As a result, it has become the largest academic exchange platform for high-level oncologists in China.

Starting from the fundamentals, we provide valuable services and products to physicians and patients. In this process, the company has gradually established competitive barriers. Currently, its professional content tailored for oncologists and cancer patients is industry-leading, making it the most important online platform for them to access cutting-edge academic knowledge.

Currently, Liangyihui operates three platforms: “Oncologist”/“Oncology Insights,” “Patient Guide Services,” and the “Global Consultation Center,” serving 120,000 oncology professionals and nearly 300,000 patients and their families. By collaborating with experts, hospitals, and professional associations, Liangyihui promotes the dissemination of cutting-edge information on precision oncology and standardizes diagnostic and treatment protocols among primary care physicians. Additionally, it assists hospitals in establishing and operating oncology medical consortia, while helping experts and multidisciplinary team (MDT) groups build their personal brands.

Liangyi Hui also actively collaborates with innovative oncology drug companies, providing patient recruitment services for clinical trials of new drugs and comprehensive marketing solutions for newly launched pharmaceuticals.

Wang Jue told VCBeat that the company has shifted its focus from serving oncologists to serving cancer patients. In addition to providing guidance and popularizing scientific knowledge, they are evolving from merely disseminating information to delivering comprehensive services. They have established a remote consultation platform connecting senior and junior physicians, leveraging the power of the internet to enable senior specialists to directly support and assist junior doctors and hospitals with their expertise. This initiative aims to standardize and enhance the quality of cancer diagnosis and treatment. It significantly addresses the imbalance in oncology medical resources—a major pain point in cancer care—and aligns with the service models strongly advocated by China’s tiered diagnosis and treatment system and the “Internet Plus Healthcare” initiative.

It is understood that Liangyihui’s products have already reached more than 60% of oncology-related physicians in China, placing the company at the forefront of the industry in terms of physician coverage. Wang Jue told VCBeat that the company’s next phase will focus on providing in-depth services to physician users, enhancing user stickiness, integrating into clinical care activities between doctors and patients, and creating value for users.